{"id":"W4390990818","doi":"10.1016/j.clml.2024.01.007","title":"Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"Kite Pharma; Genentech; Daiichi Sankyo Europe; Gilead Sciences; Servier; Astellas Pharma; bluebird bio; H. Lundbeck A/S; Syndax Pharmaceuticals; Argenx; Arog Pharmaceuticals; Pharmacyclics; Agios Pharmaceuticals; Loxo Oncology; Astex Pharmaceuticals; Jazz Pharmaceuticals; Pfizer; Incyte; F. Hoffmann-La Roche; Ablynx; AbbVie; Sanofi; GlaxoSmithKline; Amgen; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Venetoclax; Medicine; Internal medicine; Neutropenia; Nausea; Gastroenterology; Febrile neutropenia; Salvage therapy; Mucositis; Oncology; Chemotherapy regimen; Refractory (planetary science); Leukemia; Chemotherapy; Biology; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001101135,0.0007135002,0.000811366,0.0002146283,0.0002338567,0.0006846684,0.0005198497,0.0007976142,0.004732736],"category_scores_gemma":[0.0006934227,0.0002142519,0.0005582828,0.0002772263,0.0003852441,0.0003792443,0.0002683585,0.001890715,0.0006286222],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007020546,"about_ca_system_score_gemma":0.001007927,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007936796,"about_ca_topic_score_gemma":0.00271027,"domain_scores_codex":[0.9997841,0.0001058944,0.000009123755,0.00003916823,0.00002041849,0.00004128532],"domain_scores_gemma":[0.9996096,0.00007221889,0.0001122063,0.00002113562,0.00001786336,0.0001669427],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.74181,0.01732068,0.00625431,0.002098532,0.001224232,0.0002880194,0.0002434984,0.003096228,0.0275953,0.0005391205,0.01459477,0.1849354],"study_design_scores_gemma":[0.843064,0.1254167,0.01758741,0.0001745255,0.0006222089,0.0007366743,0.00005505139,0.001905071,0.00257644,0.0002540552,0.007578943,0.00002886056],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9834582,0.00995213,0.0001996813,0.0008684886,0.0001381432,0.00103493,0.001143511,0.0001115864,0.003093414],"genre_scores_gemma":[0.9867929,0.004839222,0.001003732,0.0009050653,0.0001777991,0.0009594585,0.00223969,0.00001860278,0.003063552],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004732736,"threshold_uncertainty_score":0.01583254,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05177241847446667,"score_gpt":0.4032015996761817,"score_spread":0.351429181201715,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}